At a glance
ClinicalIndex Comparison RecordN/ACompleted· 400,000 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
In Brief
An observational study for Atrial Fibrillation. Completed, enrolled 400,000 participants.
Detailed Summary
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention treatment among AF patients. The study with cohort design is conducted as a nationwide retrospective register-based linkage study using data obtained from the Finnish health care registers.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
Countries--
CollaboratorsAalto University, University of Turku
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
Primary CompletionDec 2018
First PostedNov 2020
TodayJul 2026
First PostedNov 27, 2020
Enrollment StartJul 1, 2011
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 5.6 years ago